Developing
life-changing
GENETIC MEDICINES

Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome

Neurogene and Neoleukin Announce Definitive Merger Agreement

Neurogene / Neoleukin Conference Call Discussing Merger Agreement to Create Clinical-Stage Company Focused on Differentiated Portfolio of Genetic Medicines for Complex Neurological Diseases

Neurogene Announces FDA Clearance of IND for NGN-401 Gene Therapy for Children with Rett Syndrome

Neurogene Announces New Development Program in Rett Syndrome Utilizing Novel EXACT Technology Platform

Neurogene Announces FDA Clearance of IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease

Neurogene Announces EMA Grants Orphan Drug Designation to CLN5 Batten Disease Gene Therapy

Neurogene’s AAV Biodistribution Study Shows Route of Administration Essential Component in Optimizing Gene Therapy Treatment for Neurological Disease

Neurogene and University of Edinburgh Announce Research Collaboration to Advance Next Generation Gene Therapies

Neurogene Closes $115 Million Series B Financing

Neurogene Announces EMA Grants Orphan Drug Designation for Aspartylglucosaminuria Gene Therapy

Neurogene Announces First Patient Enrolled in Natural History Study Evaluating Two Subtypes of Batten Disease

Neurogene Appoints Industry Veteran Robert A. Baffi, Ph.D. to Board of Directors

Neurogene Announces FDA Orphan Drug Designation for CLN7 Batten Disease Gene Therapy

FDA Grants Orphan Drug Designation to Neurogene’s Gene Therapy for the Treatment of CLN5 Batten Disease

Neurogene Joins Behind the Seizure^® Program, Sponsors Genetic Testing for Children with Seizures

Neurogene Appoints Christine Mikail as President

Neurogene Offers Access to Genetic Testing to Patients Suspected of Having a Lysosomal Storage Disease

Neurogene Initiates Natural History Study of Charcot-Marie Tooth Disease (CMT4J)

Neurogene Appoints Industry Leaders Dr. Sukumar Nagendran and Dr. Serge Stankovic to Board of Directors

Neurogene Raises $68.5 Million in Series A Financing to Advance Multiple Programs in Devastating Neurological Diseases

Neurogene Announces Presentation of Preclinical Data for Gene Therapies to Treat AGU and CMT4J, Two Rare and Devastating Neurodegenerative Disorders

Neurogene Appoints Stuart Cobb, Ph.D. as Chief Scientific Officer